NASDAQ:CSBR - Nasdaq - US15870P3073 - Common Stock - Currency: USD
NASDAQ:CSBR (8/7/2025, 12:48:23 PM)
6.3
-0.25 (-3.82%)
The current stock price of CSBR is 6.3 USD. In the past month the price decreased by -26.49%. In the past year, price increased by 46.86%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 20.83 | 172.15B | ||
DHR | DANAHER CORP | 26.34 | 142.00B | ||
A | AGILENT TECHNOLOGIES INC | 21.05 | 32.29B | ||
IQV | IQVIA HOLDINGS INC | 15.54 | 30.31B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 29.91 | 25.42B | ||
WST | WEST PHARMACEUTICAL SERVICES | 34.72 | 17.38B | ||
WAT | WATERS CORP | 22.8 | 16.60B | ||
ILMN | ILLUMINA INC | 22.72 | 14.96B | ||
ICLR | ICON PLC | 11.87 | 12.22B | ||
MEDP | MEDPACE HOLDINGS INC | 31.82 | 12.02B | ||
QGEN | QIAGEN N.V. | 20.49 | 10.43B | ||
RVTY | REVVITY INC | 17.65 | 10.17B |
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 210 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
CHAMPIONS ONCOLOGY INC
One University Plaza,, Suite 307
Hackensack NEW JERSEY 07601 US
CEO: Ronnie Morris
Employees: 210
Phone: 12018088400
The current stock price of CSBR is 6.3 USD. The price decreased by -3.82% in the last trading session.
The exchange symbol of CHAMPIONS ONCOLOGY INC is CSBR and it is listed on the Nasdaq exchange.
CSBR stock is listed on the Nasdaq exchange.
7 analysts have analysed CSBR and the average price target is 12.24 USD. This implies a price increase of 94.29% is expected in the next year compared to the current price of 6.3. Check the CHAMPIONS ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CHAMPIONS ONCOLOGY INC (CSBR) has a market capitalization of 86.81M USD. This makes CSBR a Micro Cap stock.
CHAMPIONS ONCOLOGY INC (CSBR) currently has 210 employees.
CHAMPIONS ONCOLOGY INC (CSBR) has a support level at 6.27 and a resistance level at 6.56. Check the full technical report for a detailed analysis of CSBR support and resistance levels.
The Revenue of CHAMPIONS ONCOLOGY INC (CSBR) is expected to grow by 7.8% in the next year. Check the estimates tab for more information on the CSBR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CSBR does not pay a dividend.
CHAMPIONS ONCOLOGY INC (CSBR) will report earnings on 2025-09-09.
The PE ratio for CHAMPIONS ONCOLOGY INC (CSBR) is 14. This is based on the reported non-GAAP earnings per share of 0.45 and the current share price of 6.3 USD. Check the full fundamental report for a full analysis of the valuation metrics for CSBR.
The outstanding short interest for CHAMPIONS ONCOLOGY INC (CSBR) is 1.05% of its float. Check the ownership tab for more information on the CSBR short interest.
ChartMill assigns a technical rating of 3 / 10 to CSBR. When comparing the yearly performance of all stocks, CSBR is one of the better performing stocks in the market, outperforming 84.12% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to CSBR. CSBR has an average financial health and profitability rating.
Over the last trailing twelve months CSBR reported a non-GAAP Earnings per Share(EPS) of 0.45. The EPS increased by 191.84% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 8.26% | ||
ROA | 14.53% | ||
ROE | 124.63% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 83% to CSBR. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -50.13% and a revenue growth 7.8% for CSBR